SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility

22 Mar 2025 Evaluate

SMS Pharmaceuticals (SMS Pharma) has successfully completed a US Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility situated at Bachupally, Hyderabad, Telangana.

The inspection, conducted from March 17, 2025 to March 21, 2025, concluded with one observation in Form 483. The observation is procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a 120 KL manufacturing capacity for niche small-volume and high-value molecules. It has multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA and CDSCO. 

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers.


SMS Pharmaceuticals Share Price

212.70 3.60 (1.72%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...